Status:
UNKNOWN
Bipolar Hemostatic Forceps Versus Standard Therapy in Acute Non-variceal Upper GI Bleeding
Lead Sponsor:
Theresienkrankenhaus und St. Hedwig-Klinik GmbH
Collaborating Sponsors:
PENTAX Europe GmbH
Conditions:
Gastrointestinal Hemorrhage
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Bipolar hemostatic forceps will be tested against standard therapy in active, non-variceal, upper gastrointestinal bleeding by a prospective, randomized trial
Detailed Description
Patients with active, non-variceal, upper gastrointestinal bleeding usually need an urgent endoscopic treatment. The standard therapy by application of an hemoclip and/or injection of an epinephrine s...
Eligibility Criteria
Inclusion
- Active, nonvariceal, upper gastrointestinal bleeding
Exclusion
- Severe coagulopathy unresponsive to blood products transfusions: platelets \<20,000; international normalized ratio \>3.0; partial thromboplastin time \>2 normal
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05353062
Start Date
January 1 2023
End Date
February 1 2024
Last Update
January 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helios Kliniken Schwerin
Schwerin, Germany, 19055